HLA-A3 Antigen (HLA A3 Antigen)

02/01/2008 - "E75 is safe and effective in raising a dose-dependent HER2/neu immunity in HLA-A2 and HLA-A3 NP and NN breast cancer patients. "
09/01/1999 - "These CTL lines were also cytotoxic against HLA-A2 and HLA-A3 breast cancer cells but not against normal fibroblastoid cell lines, normal epidermal cell lines, or a melanoma cell line. "

01/01/2011 - "Irish people with two HLA-A3 alleles had a high risk of hemochromatosis. "
09/01/2004 - "The mutation responsible for most cases of genetic haemochromatosis in Europe (HFE C282Y) appears to have been originated as a unique event on a chromosome carrying HLA-A3 and -B7. "
03/01/2002 - "Most Caucasian patients with hereditary hemochromatosis (HH) are homozygous for HLA-A3 and for the C282Y mutation of the HFE gene, while a minority are compound heterozygotes for C282Y and H63D. "
01/01/2001 - "A woman who inherited C282Y also possessed HLA-A3, -B7 which is considered part of the ancestral haplotype containing the gene predisposing to hemochromatosis in Caucasians. "
06/01/1997 - "HLA-A3 was used as the marker for the hemochromatosis gene in the population studied. "

10/01/1999 - "Of the tumor lines transfected with HLA-A3 only the human kidney tumor cell line was lysed at a level equal to the original kidney epithelial cell used to develop the clone. "
11/01/2009 - "We previously reported peptide vaccine candidates for HLA-A3 supertype (-A3, -A11, -A31, -A33)-positive cancer patients. "
04/01/2007 - "New peptide vaccine candidates for epithelial cancer patients with HLA-A3 supertype alleles."
02/01/2004 - "We identified new peptide vaccine candidates for HLA-A3, -A11, -A31, and -A33 positive cancer patients. "
11/01/2001 - "Given the expression of HLA-A2 and HLA-A3 antigen in the general population, these findings extend the potential applicability of hTERT as a therapeutic target to >60% of all cancer patients. "

05/08/1992 - "The pattern of cytotoxicity against a panel of HLA-typed melanoma cells and inhibition by (polyclonal) HLA-typing sera suggested the CD8+ CTL were restricted by HLA-A3. "
12/15/2003 - "We previously established a melanoma-reactive cytotoxic T lymphocyte (CTL) line that recognizes multiple epitopes in the context of HLA-A3. "
11/09/1998 - "Of 7 peptides tested, 2 (gp100[9(87)] and gp100[10(86)]) induced CTLs that killed melanoma cell lines expressing HLA-A3 and gp100. "
11/09/1998 - "Herein, HLA-A3 binding, gp100-derived synthetic peptides were tested for their capacity to elicit anti-melanoma CTL in vitro using CD8+ T cells from healthy donors as responders and peptide-pulsed autologous dendritic cells as antigen-presenting cells. "
04/01/1997 - "Thus although a significant percentage of Caucasians express HLA-A3, no melanoma-associated antigenic peptide presented by this allele has yet been identified. "

05/01/2015 - "The EZH2733-741 peptide-stimulated and purified CD8(+) T cells from PBMCs of HLA-A3 supertype allele(+) prostate cancer patients showed higher cytotoxicity against HLA-A3 supertype allele-expressing LNCaP prostate cancer cells than against parental LNCaP cells. "
05/01/2015 - "Five EZH2-derived peptides that were prepared based on the binding motif to the HLA-A3 supertype alleles (HLA-A11, -A31, and -A33) were functionally screened for their potential to induce peptide-specific CTLs from peripheral blood mononuclear cells (PBMCs) of HLA-A3 supertype allele(+) prostate cancer patients. "
10/01/2005 - "Antibody blocking and cold inhibition experiments revealed that the HLA-A3 supertype-restricted cytotoxicity against prostate cancer cells could be ascribed to peptide-specific and CD8+ T cells. "
10/01/2005 - "Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles."
05/01/2015 - "These results indicate that the EZH2733-741 peptide could be a promising candidate for peptide-based immunotherapy for HLA-A3 supertype allele(+) prostate cancer patients."